Jaime Rossello Coll’s Post

Have you ever wondered what makes Silica Corpora unique? At Silica Corpora, our approach to success goes beyond the surface. Instead of focusing on specific Antibody properties, our algorithm is capable of taking into account the whole system entirely, considering every aspect needed to design successful preclinical candidates. By embracing this holistic approach, we unlock unique insights and possibilities, setting us apart as leaders in innovation and excellence. Interested to learn more about us? Check out our webpage and request our whitepaper: https://lnkd.in/eNyucBPu #SilicaCorpora #DrugDesign #BioTech #TogetherForBetter

🌟 New Technological Chapter at Mabion! 🌟 We are thrilled to announce that Mabion S.A. has recently acquired the cutting-edge Beacon Select™ System for cell line development (CLD). This optofluidic system will further improve our proficiency in identifying the top-producing clones with favorable product quality attributes, ensuring the process completion within just 5 days of cloning. Key features of the Beacon Select System include: 🔸 Advanced technology: Patented Opto-ElectroPositioning (OEP™) technology uniquely enables the selective movement of cells using low intensity light to position then into NanoPen™ chambers (0.2 - 2 nanoliter holding chambers for individual cells). 🔸 Quality assays: The placement of a single cell in a NanoPen™ chamber allows a game-changing experimentation and further interrogation on the single-cell level by a variety of different assays – binding assays, fluorescence assays, morphological and phenotypic assays. 🔸 Time-saving throughput: The Beacon Select™ ensures throughput scalability without compromising efficiency. They enable us to select clones with favorable product quality attributes, reducing overall costs, improving cloning efficiency, and significantly shortening timelines by identifying top clones for scale-up. 🔸 Environmental friendliness: By significantly reducing the use of reagents, single-use materials and waste generated, this environmentally friendly device significantly reduces Mabion's carbon footprint and underlines its commitment to responsible and sustainable biotechnology practices. This automated process minimizes human intervention, encompassing enrichment, cloning, culture, assay, selection, and recovery in a single streamlined workflow. This stands in stark contrast to conventional clone selection methods, where multiple steps must be performed sequentially on various instruments. We extend our gratitude to everyone involved in this milestone project and appreciate the ongoing support from our partners from #Bruker. Together we drive innovation in biotechnology and open new opportunities for our customers! 🌟 A big thank you for preparing a substantive post for our experts Olga Grzyb & Małgorzata Nosek! 🧡 #Mabion #BiotechnologicalInnovations #CellLineDevelopment #BeaconSelectSystem #OptofluidicTechnology #Pharmaceuticals #CDMO #SustainableBiotech

Our CTO - Richard Hammond shares his insights In the latest Biocompare article on cell line development, discussing the importance of integrating product quality with factory quality right from the beginning of the cell line development process! "You can’t split factory quality and product quality. Instead, we need to bring them together and ask what is the true definition of quality for that system, which we can answer by thinking about how to screen both sides of the problem simultaneously and then building the tools and techniques to do so." - Richard Hammond, CTO of Sphere Fluidics Read more about the innovative approaches in cell line development and how Sphere Fluidics is contributing to this vital field: Cell Line Development in Drug Discovery. 👉https://bit.ly/4cbosGF #DrugDiscovery #Biotech #CellLineDevelopment #Innovation

🚀New solutions for 2024! We are excited to announce our latest investment - Oryl Photonics. This deal, adeptly led by our investment partners Jaques Schmidt and David Campbell, marks a significant milestone for us. 🔬The first machine especially designed for solubility measurements: Under the leadership of co-founders Orly Tarun and Nathan Dupertuis, Oryl Photonics is revolutionizing the world of solubility measurements in the pharmaceutical and biotech industries, as well as the academic sector. The challenge has always been measuring solubility effectively and efficiently - a crucial factor in drug development, for example. Traditional methods either compromise on speed or accuracy. Oryl Photonics is tackling this head-on with their innovative approach, applying second-harmonic scattering to accurately detect the solubility of drug compounds while using minimal amounts in different liquids. Their technology is set to transform how industries approach solubility measurements, making it faster, more reliable, and cost-effective. #S2SVentures #Investment #Innovation #Pharmaceuticals #Biotech #OrylPhotonics #SolubilityMeasurement #TechRevolution #Photonics

We're proud to support Mesentech, a pioneering Vancouver-based biotech startup, to innovate targeted drug delivery with their cutting-edge small molecule therapeutics. Their first clinical program, aimed at promoting musculoskeletal tissue regeneration, is set to have a significant impact while minimizing organ toxicity.     Dr. Gang Chen, Director of Medicinal Chemistry at Mesentech, beautifully captures the value of using ChemAIRS from Chemical.AI: “𝘜𝘵𝘪𝘭𝘪𝘻𝘪𝘯𝘨 𝘊𝘩𝘦𝘮𝘈𝘐𝘙𝘚 𝘧𝘳𝘰𝘮 𝘊𝘩𝘦𝘮𝘪𝘤𝘢𝘭.𝘈𝘐 𝘪𝘴 𝘢𝘯𝘢𝘭𝘰𝘨𝘰𝘶𝘴 𝘵𝘰 𝘪𝘯𝘤𝘰𝘳𝘱𝘰𝘳𝘢𝘵𝘪𝘯𝘨 𝘢 𝘤𝘩𝘦𝘮𝘪𝘴𝘵 𝘸𝘪𝘵𝘩 𝘥𝘦𝘤𝘢𝘥𝘦𝘴 𝘰𝘧 𝘦𝘹𝘱𝘦𝘳𝘪𝘦𝘯𝘤𝘦 𝘪𝘯𝘵𝘰 𝘺𝘰𝘶𝘳 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘵𝘦𝘢𝘮. 𝘛𝘩𝘦𝘴𝘦 𝘴𝘶𝘨𝘨𝘦𝘴𝘵𝘦𝘥 𝘳𝘦𝘢𝘤𝘵𝘪𝘰𝘯𝘴 𝘢𝘳𝘦 𝘤𝘩𝘦𝘮𝘪𝘤𝘢𝘭𝘭𝘺 𝘱𝘭𝘢𝘶𝘴𝘪𝘣𝘭𝘦, 𝘵𝘩𝘰𝘶𝘨𝘩 𝘵𝘩𝘦𝘺 𝘮𝘢𝘺 𝘯𝘰𝘵 𝘩𝘢𝘷𝘦 𝘣𝘦𝘦𝘯 𝘱𝘳𝘦𝘷𝘪𝘰𝘶𝘴𝘭𝘺 𝘦𝘮𝘱𝘭𝘰𝘺𝘦𝘥 𝘵𝘰 𝘴𝘺𝘯𝘵𝘩𝘦𝘴𝘪𝘻𝘦 𝘴𝘪𝘮𝘪𝘭𝘢𝘳 𝘤𝘰𝘮𝘱𝘰𝘶𝘯𝘥𝘴".    By leveraging ChemAIRS' advanced retrosynthesis and condition search capabilities, Mesentech is speeding up the creation of innovative synthetic routes, optimizing processes with cost-effective materials, and significantly reducing waste. The flexibility of ChemAIRS empowers their chemists to quickly adapt to project needs, ensuring that every step from concept to execution is as efficient and effective as possible. Read the full case study below.    #Biotech #Innovation #AI #DrugDevelopment #ChemicalAI #Mesentech #SyntheticChemistry #Pharma

The best way to fast-track your antibody to the clinic is to have a bullet-proof #antibodydiscovery plan! Tackle affinity, function, developability, altogether! #antibodies #FairJourneyBiologics

𝐄𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐇𝐢𝐠𝐡 𝐓𝐡𝐫𝐨𝐮𝐠𝐡𝐩𝐮𝐭 𝐒𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐫𝐚𝐛 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/gKYYRdSx The global high throughput screening market in terms of revenue was estimated to be worth $25.7 billion in 2023 and is poised to reach $44.5 billion by 2028, growing at a CAGR of 11.6% from 2023 to 2028. The growth of this market is driven by increasing R&D spending in the HTS market. Increased R&D spending can serve as a driving force for the HTS market due to expanded #drugdiscovery efforts, a focus on personalized medicine, technological advancements, and collaborative research efforts. 𝐊𝐞𝐲 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬: Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, Darmstadt, Germany, Danaher Corporation, PerkinElmer, Tecan, Axxam, Promega Corporation, Bio-Rad Laboratories, Promega Corporation , Hamilton Company, Corning Incorporated, Charles River Laboratories, Lonza, REPROCELL, Aurora Biomed Inc. , BMG LABTECH, DIANA Biotechnologies, NanoTemper Technologies, Creative Biolabs, Biomat Srl | Coated 96 Well Plates for ELISA & other Immunoassays & PCR Tubes and Plates, HighRes Biosolutions, Cyclica (acquired by Recursion, Nasdaq: RXRX), Crown Bioscience, and Sygnature Discovery #HighThroughputScreening #HTS #DrugDiscovery #Biotech #PharmaResearch #BiomedicalResearch #LabAutomation

**𝐏𝐫𝐨𝐮𝐝 𝐭𝐨 𝐒𝐮𝐩𝐩𝐨𝐫𝐭 𝐂𝐨𝐧𝐯𝐄𝐲𝐗𝐎 𝐢𝐧 𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐢𝐧𝐠 𝐀𝐧𝐭𝐢-𝐈𝐧𝐟𝐥𝐚𝐦𝐦𝐚𝐭𝐨𝐫𝐲 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬** At 𝐌𝐚𝐧𝐞𝐭𝐜𝐨, We are thrilled to highlight our collaboration with 𝐂𝐨𝐧𝐯𝐄𝐲𝐗𝐎, a company committed to promoting healthier lifespans through the development of anti-inflammaging and anti-inflammatory therapeutics. 𝐁𝐲 𝐮𝐧𝐥𝐨𝐜𝐤𝐢𝐧𝐠 𝐭𝐡𝐞 𝐭𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐯𝐞 𝐩𝐨𝐰𝐞𝐫 𝐨𝐟 𝐞𝐱𝐭𝐫𝐚𝐜𝐞𝐥𝐥𝐮𝐥𝐚𝐫 𝐯𝐞𝐬𝐢𝐜𝐮𝐥𝐞𝐬 (𝐄𝐕𝐬), 𝐂𝐨𝐧𝐯𝐄𝐲𝐗𝐎 is addressing high-prevalence unmet medical needs.   To achieve the required EV loading performance without damaging these vital vesicles, 𝐂𝐨𝐧𝐯𝐄𝐲𝐗𝐎 utilizes nanofluidic technology developed by XomeXbio. At 𝐌𝐚𝐧𝐞𝐭𝐜𝐨, we had the privilege of designing and developing 𝐫𝐨𝐛𝐮𝐬𝐭 𝐦𝐢𝐜𝐫𝐨𝐟𝐥𝐮𝐢𝐝𝐢𝐜 𝐞𝐪𝐮𝐢𝐩𝐦𝐞𝐧𝐭 𝐭𝐡𝐚𝐭 𝐩𝐫𝐨𝐜𝐞𝐬𝐬𝐞𝐬 𝐄𝐕 𝐥𝐨𝐚𝐝𝐢𝐧𝐠 𝐰𝐢𝐭𝐡 𝐩𝐫𝐞𝐜𝐢𝐬𝐞 𝐟𝐥𝐨𝐰 𝐜𝐨𝐧𝐭𝐫𝐨𝐥 𝐚𝐧𝐝 𝐆𝐌𝐏 𝐜𝐨𝐦𝐩𝐥𝐢𝐚𝐧𝐜𝐞 𝐜𝐚𝐩𝐚𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬.   Working closely with the 𝐂𝐨𝐧𝐯𝐄𝐲𝐗𝐎 team, we identified the main components necessary for the process, such as specialized pumps. We began with a minimum viable product (MVP) of the equipment, incorporating essential components to validate performance for the microfluidic process. This collaboration evolved into the selection and development of automated equipment that now efficiently runs all their experiments.   A big thank you to the 𝐂𝐨𝐧𝐯𝐄𝐲𝐗𝐎 team for this fantastic collaboration! We're proud to be part of this journey towards revolutionizing EV manufacturing and loading.   #Manetco #ConvEyXO #Collaboration #Microfluidics #ExtracellularVesicles #Innovation #Biotechnology

Want to boost the efficiency and success of your drug discovery research? Learn about MicroMapping and DNA-encoded library (DEL) technology in our upcoming webinar. Register to view live or on-demand!

Want to boost the efficiency and success of your drug discovery research? Learn about MicroMapping and DNA-encoded library (DEL) technology in our upcoming webinar. Register to view live or on-demand!